ClearPoint Neuro (CLPT) Projected to Post Earnings on Thursday

ClearPoint Neuro (NASDAQ:CLPT) will likely be announcing its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect ClearPoint Neuro to post earnings of ($0.20) per share and revenue of $9.60 million for the quarter. ClearPoint Neuro has set its FY 2025 guidance at EPS.Individuals are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, November 6, 2025 at 4:30 PM ET.

ClearPoint Neuro (NASDAQ:CLPT) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.01). ClearPoint Neuro had a negative return on equity of 94.44% and a negative net margin of 66.15%.The firm had revenue of $9.22 million for the quarter, compared to analysts’ expectations of $9.20 million. On average, analysts expect ClearPoint Neuro to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

ClearPoint Neuro Stock Down 10.6%

ClearPoint Neuro stock opened at $24.11 on Thursday. The company has a market capitalization of $685.45 million, a P/E ratio of -29.77 and a beta of 1.19. The company has a debt-to-equity ratio of 1.46, a quick ratio of 6.45 and a current ratio of 7.30. ClearPoint Neuro has a fifty-two week low of $9.76 and a fifty-two week high of $30.10. The stock has a 50-day simple moving average of $18.11 and a 200-day simple moving average of $14.19.

Insider Buying and Selling at ClearPoint Neuro

In related news, CEO Joseph Burnett sold 26,463 shares of the stock in a transaction on Friday, October 10th. The stock was sold at an average price of $26.98, for a total transaction of $713,971.74. Following the completion of the sale, the chief executive officer directly owned 217,059 shares of the company’s stock, valued at $5,856,251.82. This trade represents a 10.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 6.97% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On ClearPoint Neuro

A number of large investors have recently bought and sold shares of CLPT. BNP Paribas Financial Markets lifted its stake in shares of ClearPoint Neuro by 2,435.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,231 shares of the company’s stock worth $27,000 after acquiring an additional 2,143 shares during the period. Legal & General Group Plc purchased a new position in ClearPoint Neuro during the second quarter worth about $35,000. Raymond James Financial Inc. acquired a new stake in ClearPoint Neuro in the second quarter valued at about $80,000. Osaic Holdings Inc. boosted its holdings in ClearPoint Neuro by 119.8% in the 2nd quarter. Osaic Holdings Inc. now owns 7,705 shares of the company’s stock valued at $92,000 after purchasing an additional 4,200 shares in the last quarter. Finally, New York State Common Retirement Fund acquired a new position in ClearPoint Neuro during the 2nd quarter worth approximately $100,000. Hedge funds and other institutional investors own 30.08% of the company’s stock.

Analysts Set New Price Targets

CLPT has been the subject of a number of research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of ClearPoint Neuro in a research note on Wednesday, October 8th. Wall Street Zen raised shares of ClearPoint Neuro from a “sell” rating to a “hold” rating in a report on Saturday, September 13th. Finally, Stifel Nicolaus upped their price target on shares of ClearPoint Neuro from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Friday, August 1st. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, ClearPoint Neuro has a consensus rating of “Moderate Buy” and a consensus price target of $19.67.

About ClearPoint Neuro

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.